FDA Grants Orphan Status to OCT-980 for Vision Loss
The designation provides seven years of market exclusivity to help move the AI-designed therapy through clinical trials.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Should the government provide financial incentives for companies to develop treatments for rare diseases?
The FDA has granted orphan drug designation to Octant’s drug candidate OCT-980 for the treatment of rhodopsin-associated autosomal dominant retinitis pigmentosa. This research-stage oral therapy is currently undergoing a Phase I/II clinical study to address gradual vision loss.
Why it matters
The orphan drug designation accelerates the development of specialized therapies for rare diseases by providing financial incentives and regulatory exclusivity. This status recognizes the potential of OCT-980 to serve as a disease-modifying treatment for patients with a specific genetic form of vision loss.
The orphan drug designation grants seven years of US market exclusivity and provides tax credits on clinical trials, far exceeding the protections for non-orphan therapies. The candidate, OCT-980, currently under investigation, aims to function as an oral treatment.
The players
Octant
A drug discovery company using synthetic biology, generative chemistry, and AI to develop small-molecule therapeutics for rare diseases.
FDA
The United States federal agency responsible for regulating drug approvals and granting orphan drug designations to incentivize rare disease research.
The details
OCT-980 uses a therapeutic mechanism designed to correct protein misfolding, the primary cause of rhodopsin-associated autosomal dominant retinitis pigmentosa. By restoring the normal cellular trafficking of rhodopsin—a protein responsible for light absorption in the eye—the drug targets the biological root of vision loss. Octant uses a discovery platform integrating generative chemistry, synthetic biology, and AI to identify these compounds.
Timeline
October 28, 2026: FDA granted orphan drug designation for OCT-980.
The Tech Race
This development aligns with the FDA Orphan Drug Act, which formalizes the research trajectory for rare disease treatments. The classification marks a milestone for Octant in the competitive landscape of AI-driven drug discovery, prioritizing high-precision interventions for genetic conditions.
For patients with rhodopsin-associated autosomal dominant retinitis pigmentosa, this designation marks a critical step toward a potential disease-modifying oral treatment. The therapy remains in a research-stage Phase I/II study, and no public timeline for availability or commercial release has been announced.
The takeaway
The orphan drug designation simplifies the regulatory path for Octant as they move through clinical trials. Investors and patients should watch for the completion of the ongoing Phase I/II study, which will determine if the compound succeeds as a disease-modifying treatment.
Further reading
Learn more about the latest developments in the field at Biotech.
Source note: This article includes information reported by Pharmaceutical Technology.
Live Poll
Should the government provide financial incentives for companies to develop treatments for rare diseases?
